Overview of targeted antitumor drugs approved by FDA in recent five yearsSUN Jin, ZHU Xiao-he, WANG Shan, CHU Jian-jie, MA Zhong-ying, ZHANG En-hu, WEN Ai-dong1-6
Performance of registration regulation policies on biosimilar products in the European Union and its enlightenmentCHEN Yong-fa, WU Lin7-12
Study on American incentive policies for antibiotic research and development and the inspirationsZHANG Meng, SHAO Rong13-18
A brief introduction to the FDA's administrative policy development on generic drugsCHEN Shao-yu, LI Jun27-30
Comparative analysis of rare disease pharmaceutical policies of China and AmericaZHAO Ying, LIU Ai-lin, DU Guan-hua31-35,49
Repeated dose toxicity of humanized anti-HER2 monoclonal antibody周晓冰, 孙立, 盛晓丽, 霍桂桃, 苗玉发, 朱聪, 杨艳伟, 霍艳, 王雪36-41
Local lymph node assay and research progress in revised LLNA for evaluation of skin sensitizationDU Wen-wan, HUANG Zhi-ying, LIU Li42-49
Detection of anti-drug antibody against anti-BLyS antibody in cynomolgus monkey by ELISAGAO Liu-cun, LI Li, WANG Xu-jia, CHEN Fang, DONG Li-hou, OU Lun, SONG Hai-feng50-55,81